TRESIBA
(insulin degludec)PreclinicalBiologic
Novo NordiskTRESIBA is one of 40 biologic programs targeting Type 2 Diabetes Mellitus. It is currently in Preclinical.
1
Indications
0
Total Trials
0
Active Trials
39
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[2]
Indication
Competition
Competitive Landscape
676 competitors in Type 2 Diabetes Mellitus
#DrugCompanyPhaseTrials
1Tanzeum
GSKPreclinical
Insulin 320
Novo NordiskPreclinical
Adenocard
AstellasPreclinical
NOVOLIN R
Novo NordiskPreclinical
Dostinex
PfizerPreclinical
Cipro
BayerPreclinical
Myrbetriq
AstellasPreclinical
Golytely
BayerPreclinical
Lantus
SanofiPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Regulatory
FDA Approval Timeline[3]
Sep 25, 2015
TRESIBA
BLA BLA203314
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for insulin degludec. EMBL-EBI & Wellcome Sanger Institute.
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[1]
- Highest Phase
- Preclinical
- Company